72 related articles for article (PubMed ID: 25844935)
1. Down Expression of FBP1 Is a Negative Prognostic Factor for Non-Small-Cell Lung Cancer.
Sheng H; Ying L; Zheng L; Zhang D; Zhu C; Wu J; Feng J; Su D
Cancer Invest; 2015 May; 33(5):197-204. PubMed ID: 25844935
[TBL] [Abstract][Full Text] [Related]
2. Src kinase-associated phosphoprotein2 expression is associated with poor prognosis in non-small cell lung cancer.
Kuranami S; Yokobori T; Mogi A; Altan B; Yajima T; Onozato R; Azuma Y; Iijima M; Kosaka T; Kuwano H
Anticancer Res; 2015 Apr; 35(4):2411-5. PubMed ID: 25862907
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
4. Significance of Methylation of FBP1 Gene in Non-Small Cell Lung Cancer.
Dong Y; Huaying S; Danying W; Chihong Z; Ruibin J; Xiaojiang S; Jianguo F
Biomed Res Int; 2018; 2018():3726091. PubMed ID: 29984231
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
6. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
Wang L; Soria JC; Kemp BL; Liu DD; Mao L; Khuri FR
Clin Cancer Res; 2002 Sep; 8(9):2883-9. PubMed ID: 12231532
[TBL] [Abstract][Full Text] [Related]
7. Expression of far upstream element (FUSE) binding protein 1 in human glioma is correlated with c-Myc and cell proliferation.
Ding Z; Liu X; Liu Y; Zhang J; Huang X; Yang X; Yao L; Cui G; Wang D
Mol Carcinog; 2015 May; 54(5):405-15. PubMed ID: 24347226
[TBL] [Abstract][Full Text] [Related]
8. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer.
Roudi R; Madjd Z; Korourian A; Mehrazma M; Molanae S; Sabet MN; Shariftabrizi A
Cancer Biomark; 2014; 14(6):457-67. PubMed ID: 25335738
[TBL] [Abstract][Full Text] [Related]
10. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.
Võsa U; Vooder T; Kolde R; Fischer K; Välk K; Tõnisson N; Roosipuu R; Vilo J; Metspalu A; Annilo T
Genes Chromosomes Cancer; 2011 Oct; 50(10):812-22. PubMed ID: 21748820
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
12. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
13. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Wang TB; Zhang NL; Wang SH; Li HY; Chen SW; Zheng YG
Genet Mol Res; 2014 May; 13(2):3704-10. PubMed ID: 24854656
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
[TBL] [Abstract][Full Text] [Related]
15. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer.
Lin X; Gu J; Lu C; Spitz MR; Wu X
Clin Cancer Res; 2006 Oct; 12(19):5720-5. PubMed ID: 17020976
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.
Starnes SL; Pathrose P; Wang J; Succop P; Morris JC; Bridges J; Kupert EY; Anderson M
Ann Thorac Surg; 2012 May; 93(5):1606-12. PubMed ID: 22440368
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of nm23-H1 in stage I non-small cell lung cancer: a useful marker in prediction of metastases.
Lai WW; Wu MH; Yan JJ; Chen FF
Ann Thorac Surg; 1996 Nov; 62(5):1500-4. PubMed ID: 8893591
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of EIF4A2 in non-small-cell lung cancer associates with poor prognosis.
Shaoyan X; Juanjuan Y; Yalan T; Ping H; Jianzhong L; Qinian W
Clin Lung Cancer; 2013 Nov; 14(6):658-65. PubMed ID: 23867391
[TBL] [Abstract][Full Text] [Related]
19. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
